GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vivani Medical Inc (NAS:VANI) » Definitions » EV-to-EBIT

Vivani Medical (Vivani Medical) EV-to-EBIT : -3.65 (As of May. 08, 2024)


View and export this data going back to 2022. Start your Free Trial

What is Vivani Medical EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Vivani Medical's Enterprise Value is $98.45 Mil. Vivani Medical's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-26.97 Mil. Therefore, Vivani Medical's EV-to-EBIT for today is -3.65.

The historical rank and industry rank for Vivani Medical's EV-to-EBIT or its related term are showing as below:

VANI' s EV-to-EBIT Range Over the Past 10 Years
Min: -148.34   Med: 0   Max: 0.73
Current: -3.65

During the past 4 years, the highest EV-to-EBIT of Vivani Medical was 0.73. The lowest was -148.34. And the median was 0.00.

VANI's EV-to-EBIT is ranked worse than
100% of 426 companies
in the Biotechnology industry
Industry Median: 9.545 vs VANI: -3.65

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Vivani Medical's Enterprise Value for the quarter that ended in Dec. 2023 was $52.09 Mil. Vivani Medical's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-26.97 Mil. Vivani Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -51.76%.


Vivani Medical EV-to-EBIT Historical Data

The historical data trend for Vivani Medical's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivani Medical EV-to-EBIT Chart

Vivani Medical Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
- - 0.05 -1.93

Vivani Medical Quarterly Data
Dec20 Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 -0.58 -1.86 -1.69 -1.93

Competitive Comparison of Vivani Medical's EV-to-EBIT

For the Biotechnology subindustry, Vivani Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vivani Medical's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vivani Medical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Vivani Medical's EV-to-EBIT falls into.



Vivani Medical EV-to-EBIT Calculation

Vivani Medical's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=98.453/-26.965
=-3.65

Vivani Medical's current Enterprise Value is $98.45 Mil.
Vivani Medical's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-26.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vivani Medical  (NAS:VANI) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Vivani Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=-26.965/52.09362
=-51.76 %

Vivani Medical's Enterprise Value for the quarter that ended in Dec. 2023 was $52.09 Mil.
Vivani Medical's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-26.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vivani Medical EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Vivani Medical's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Vivani Medical (Vivani Medical) Business Description

Traded in Other Exchanges
Address
5858 Horton Street, Suite 280, Emeryville, CA, USA, 94608
Vivani Medical Inc is a preclinical stage biopharmaceutical company. It develops miniaturized, subdermal implants utilizing its proprietary NanoPortal technology to enable long-term, near constant-rate delivery of a broad range of medicines to treat chronic diseases.
Executives
Gregg Williams director, 10 percent owner PO BOX 200, WALLED LAKE MI 48390-0200
Brigid Makes officer: CFO 20245 SW 95TH AVENUE, TUALATIN OR 97062
Donald Dwyer officer: Chief Business Officer 54 CHERRY FARM LANE, WEST CHESTER PA 19382
Aaron Mendelsohn director 224 15TH STREET, SANTA MONICA CA 90402
Joachim Eberhard Bolck 10 percent owner 33 CLUB VIEW LANE, ROLLING HILLS ESTATES CA 90274
Lisa Ellen Porter officer: Chief Medical Officer 778 CORDILLERAS AVE, SAN CARLOS CA 94070
Truc Le officer: COO 1905 WEST RED FOX ROAD, SANTA ANA CA 92704
Adam Mendelsohn director, officer: CEO C/O 5858 HORTON ST. SUITE 280, EMERYVILLE CA 94608
Wilford Dean Baker director 200 FLYNN ROAD, CAMARILLO CA 93012-8790
Larson Alexandra L.p. director 3797 BURNING TREE DRIVE, BLOOMFIELD HILLS MI 48302
Scott Dunbar officer: Acting CEO 13170 TELFAIR AVENUE, SYLMAR CA 91342
Edward Jonathon Sedo officer: Controller 4485 FORESTGLEN CT, MOORPARK CA 93021
Jessy Dana Dorn officer: VP-Clin & Scientific Affairs 12744 SAN FERNANDO RD. SUITE 400, SYLMAR CA 91342
Matthew J Pfeffer director
Patrick Ryan officer: Chief Operating Officer C/O SECOND SIGHT MEDICAL PRODUCTS, INC., 12744 SAN FERNANDO ROAD, SUITE 400, SYLMAR CA 91342